[go: up one dir, main page]

BRPI0713132B8 - compostos derivados de cinamoil-piperazina, método de preparação dos referidos compostos, composições farmacêuticas, seus usos como antagonistas de par-i e produtos - Google Patents

compostos derivados de cinamoil-piperazina, método de preparação dos referidos compostos, composições farmacêuticas, seus usos como antagonistas de par-i e produtos

Info

Publication number
BRPI0713132B8
BRPI0713132B8 BRPI0713132A BRPI0713132A BRPI0713132B8 BR PI0713132 B8 BRPI0713132 B8 BR PI0713132B8 BR PI0713132 A BRPI0713132 A BR PI0713132A BR PI0713132 A BRPI0713132 A BR PI0713132A BR PI0713132 B8 BRPI0713132 B8 BR PI0713132B8
Authority
BR
Brazil
Prior art keywords
compounds
cinnamoyl
products
preparation
pharmaceutical compositions
Prior art date
Application number
BRPI0713132A
Other languages
English (en)
Inventor
Le Grand Bruno
Lamothe Marie
Perez Michel
Letienne Robert
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of BRPI0713132A2 publication Critical patent/BRPI0713132A2/pt
Publication of BRPI0713132B1 publication Critical patent/BRPI0713132B1/pt
Publication of BRPI0713132B8 publication Critical patent/BRPI0713132B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

derivados de cinamoil-piperazina e seu uso como antagonistas par-i. trata-se de compostos da fórmula geral (i), em que: r~ 1~ representa halogênio, cn ou no~ 2~; r~ 2~ representa hidrogênio ou halogênio; n representa 1 ou 2; r~ 3~ representa fenila substituída por um ou mais halogênios ou c~ 1~-c~ 6~ alquilas; ou um cicloexil; bem como os sais ou solvatos terapeuticamente aceitáveis dessa. esses compostos são úteis como antagonistas (par-1) do receptor-1 ativado por protease, particularmente no tratamento de trombose.
BRPI0713132A 2006-06-19 2007-06-19 compostos derivados de cinamoil-piperazina, método de preparação dos referidos compostos, composições farmacêuticas, seus usos como antagonistas de par-i e produtos BRPI0713132B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0605419 2006-06-19
FR0605419A FR2902426B1 (fr) 2006-06-19 2006-06-19 Derives de cinnamoyl-piperazine
PCT/EP2007/056086 WO2007147824A1 (en) 2006-06-19 2007-06-19 Cinnamoyl-piperazine derivatives and their use as par- i antagonists

Publications (3)

Publication Number Publication Date
BRPI0713132A2 BRPI0713132A2 (pt) 2012-04-17
BRPI0713132B1 BRPI0713132B1 (pt) 2020-10-20
BRPI0713132B8 true BRPI0713132B8 (pt) 2021-05-25

Family

ID=37846050

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0713132A BRPI0713132B8 (pt) 2006-06-19 2007-06-19 compostos derivados de cinamoil-piperazina, método de preparação dos referidos compostos, composições farmacêuticas, seus usos como antagonistas de par-i e produtos

Country Status (31)

Country Link
US (2) US8217046B2 (pt)
EP (1) EP2041104B1 (pt)
JP (1) JP5356222B2 (pt)
KR (1) KR101468752B1 (pt)
CN (1) CN101472907B (pt)
AR (1) AR061520A1 (pt)
AT (1) ATE478059T1 (pt)
AU (1) AU2007263051B2 (pt)
BR (1) BRPI0713132B8 (pt)
CA (1) CA2655527C (pt)
CR (1) CR10509A (pt)
DE (1) DE602007008572D1 (pt)
EC (1) ECSP099065A (pt)
ES (1) ES2349324T3 (pt)
FR (1) FR2902426B1 (pt)
GE (1) GEP20115201B (pt)
IL (1) IL195972A (pt)
MA (1) MA30756B1 (pt)
MX (1) MX2008016447A (pt)
MY (1) MY144461A (pt)
NO (1) NO341389B1 (pt)
NZ (1) NZ573764A (pt)
PL (1) PL2041104T3 (pt)
PT (1) PT2041104E (pt)
RU (1) RU2440997C2 (pt)
SA (1) SA07280330B1 (pt)
TN (1) TNSN08522A1 (pt)
TW (1) TWI404710B (pt)
UA (1) UA96947C2 (pt)
WO (1) WO2007147824A1 (pt)
ZA (1) ZA200900303B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3014693B1 (fr) * 2013-12-16 2016-01-08 Pf Medicament Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
WO2015173802A1 (en) 2014-05-11 2015-11-19 Tel Hashomer Medical Research Infrastructure And Services Ltd. Par-1 based therapeutic conjugates and uses thereof
WO2016066789A1 (fr) * 2014-10-31 2016-05-06 Pierre Fabre Medicament Utilisation d'antagonistes par-1 pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
CN104496924B (zh) * 2015-01-13 2016-04-13 佛山市赛维斯医药科技有限公司 卤苯二烯四氮唑类化合物、其制备方法和用途
CN104529860B (zh) * 2015-01-13 2016-06-01 佛山市赛维斯医药科技有限公司 一种含硝基苯和二烯氟代金刚烷结构的化合物及制备方法
CN104496922B (zh) * 2015-01-13 2016-04-06 佛山市赛维斯医药科技有限公司 腈基苯二烯四氮唑类化合物、其制备方法和用途
CN104496879A (zh) * 2015-01-13 2015-04-08 佛山市赛维斯医药科技有限公司 一种含腈基苯和二烯氟代金刚烷结构的化合物和用途
CN105949116A (zh) * 2016-06-08 2016-09-21 青岛理工大学 酰基哌嗪类化合物及其制备方法和用途
EP3278802A1 (en) 2016-08-04 2018-02-07 Metabolys New treatment for the non alcoholic steatohepatitis and fibrosis
RU2662308C1 (ru) * 2017-12-25 2018-07-25 Феркат Адельзянович Халиуллин Средство для лечения и профилактики тромбоза
US11497793B2 (en) 2018-05-02 2022-11-15 Tel Hashomer Medical Research Infrastructure And Services Ltd. Compositions and methods for treating glioblastoma
FR3090317B1 (fr) 2018-12-19 2021-05-07 Cvasthera Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale
KR102791326B1 (ko) * 2021-09-29 2025-04-04 주성수 피페론구민계 화합물을 유효성분으로 포함하는 혈관질환 예방 또는 치료용 약학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61106564A (ja) * 1984-10-30 1986-05-24 Terumo Corp 不飽和脂肪酸アミド誘導体およびこれを含有する血小板凝集抑制剤
JPS6219577A (ja) * 1985-07-16 1987-01-28 Kanebo Ltd 新規なベンジルピペラジン誘導体および該化合物を有効成分とする医薬組成物
SE9201956D0 (sv) * 1992-06-25 1992-06-25 Kabi Pharmacia Ab Novel nicotinicacid esters
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
WO2002076965A1 (en) * 2001-03-23 2002-10-03 John Matsoukas Non peptide mimetics based on the active sequence s42fllr46 of the thrombin receptor for the treatment of thrombosis and cancer
GB0224917D0 (en) * 2002-10-25 2002-12-04 Novartis Ag Organic compounds
MXPA05004890A (es) * 2002-11-07 2005-07-22 Merck & Co Inc Derivados de fenilalanina como inhibidores de dipeptidilpeptidasa para el tratamiento o prevencion de diabetes.
CN1775762A (zh) * 2005-12-06 2006-05-24 山东大学 川芎嗪酰基哌嗪衍生物、制备方法和药物组合物与应用
FR2917622B1 (fr) * 2007-06-19 2009-10-23 Pierre Fabre Medicament Sa Utilisation d'un antagoniste par1 dans le traitement de la fibrillation atriale.

Also Published As

Publication number Publication date
PT2041104E (pt) 2010-11-08
ZA200900303B (en) 2009-12-30
DE602007008572D1 (de) 2010-09-30
FR2902426A1 (fr) 2007-12-21
CN101472907B (zh) 2012-08-29
NO20090270L (no) 2009-03-03
PL2041104T3 (pl) 2011-01-31
CR10509A (es) 2009-02-05
BRPI0713132B1 (pt) 2020-10-20
AR061520A1 (es) 2008-09-03
CA2655527A1 (en) 2007-12-27
MY144461A (en) 2011-09-30
JP2009541260A (ja) 2009-11-26
MX2008016447A (es) 2009-01-22
TWI404710B (zh) 2013-08-11
TW200808742A (en) 2008-02-16
BRPI0713132A2 (pt) 2012-04-17
ES2349324T3 (es) 2010-12-30
AU2007263051A1 (en) 2007-12-27
GEP20115201B (en) 2011-04-11
US8217046B2 (en) 2012-07-10
ECSP099065A (es) 2009-02-27
CN101472907A (zh) 2009-07-01
US20090176803A1 (en) 2009-07-09
WO2007147824A1 (en) 2007-12-27
EP2041104A1 (en) 2009-04-01
NO341389B1 (no) 2017-10-30
RU2440997C2 (ru) 2012-01-27
ATE478059T1 (de) 2010-09-15
IL195972A (en) 2014-05-28
TNSN08522A1 (en) 2010-04-14
CA2655527C (en) 2014-12-23
US20120232097A1 (en) 2012-09-13
NZ573764A (en) 2011-01-28
RU2008152247A (ru) 2010-07-27
US8513258B2 (en) 2013-08-20
SA07280330B1 (ar) 2010-10-23
HK1127353A1 (en) 2009-09-25
EP2041104B1 (en) 2010-08-18
UA96947C2 (ru) 2011-12-26
FR2902426B1 (fr) 2008-09-05
KR20090031572A (ko) 2009-03-26
MA30756B1 (fr) 2009-10-01
KR101468752B1 (ko) 2014-12-03
IL195972A0 (en) 2009-09-01
JP5356222B2 (ja) 2013-12-04
AU2007263051B2 (en) 2011-10-20

Similar Documents

Publication Publication Date Title
BRPI0713132B8 (pt) compostos derivados de cinamoil-piperazina, método de preparação dos referidos compostos, composições farmacêuticas, seus usos como antagonistas de par-i e produtos
UY30481A1 (es) Isoxazolinas sustituidas, composiciones farmaccuticas que contienen a las mismas, metodos de preparacion y usos.
GT200600518A (es) Derivados de pirimidina
NO20091893L (no) Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav.
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
BRPI0716171A8 (pt) Composto, composição farmacêutica e uso de um composto
NO20075623L (no) Benzodioksan- og benzodioksolanderivater og deres anvendelse
ECSP088871A (es) Derivados de triazolopirazina
NO20082269L (no) Nye piperaziner som antimalariamidler
ECSP055676A (es) Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia
UY30759A1 (es) Compuestos quimicos
NO20075158L (no) Nye sykliske aminer
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
BRPI0606964A2 (pt) pirrolidinas e piperidinas derivadas do acetileno para uso como antagonistas de mglur5
UY31334A1 (es) 3a,4,5,6,7,7a-hexahidro-3h-benzoimidazol y derivaods de 3a, 4,5,6,,7,7a-hexahidro-3-indol, enantiómeros, diastereoisómeros, sales farmacéuticamente aceptadas, mezclas, composiciones, preparaciones y aplicaciones de las mismas
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
BRPI0811275B8 (pt) derivado de 1,3-di-hidroimidazol-2-tiona como inibidor da dopamina-beta-hidroxilase, processo para a preparação do mesmo, composição farmacêutica, e, uso do mesmo
UY31141A1 (es) Compuestos de piperidina y sus usos
BRPI0720742B8 (pt) derivados de heteroaril pirrolidinil e piperidinil cetona, seus usos e composição farmacêutica compreendo os mesmos
UY29892A1 (es) Nuevos derivados de cromano, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones
UY28536A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
UY30363A1 (es) Derivados sustituidos de la n-(3-oxo-2,3-dihidro-1h-isoindol-4-il)-1-naftamida, procesos de preparacion, composiciones farmacéuticas y aplicaciones
BR112015023356A2 (pt) inibidores de quinase pirrol[2,3-b]piridina cdk9
UY29739A1 (es) Derivados de amidas o sales farmacéuticamente aceptables de los mismos, procesos de preparaciones farmacéuticas conteniéndolos y aplicaciones
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/06/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2675 DE 12-04-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.